Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven Hersch

Showing results (31-40 of 47) with videos related to

Pageof 5
Sort By:
Neurobiology of Disease|July 12, 2014
Altered selenium status in Huntington's disease: neuroprotection by selenite in the N171-82Q mouse modelZhen Lu, Eileen Marks, Jianfang Chen, et al.
Plos Currents|September 30, 2010
Evaluation of histone deacetylases as drug targets in Huntington's disease models. Study of HDACs in brain tissues from R6/2 and CAG140 knock-in HD mouse models and human patients and in a neuronal HD cell modelLuisa Quinti, Vanita Chopra, Dante Rotili, et al.
The Journal of Prevention of Alzheimer'S Disease|February 14, 2026
Lecanemab for treatment of individuals with early Alzheimer's Disease (AD) who are apolipoprotein E ε4 (ApoE ε4) non-carriers or heterozygotesRichard Perry, Christopher Kipps, Maria Eugenia Soto Martín, et al.
The Journal of Prevention of Alzheimer'S Disease|March 14, 2026
Corrigendum to "Lecanemab for treatment of individuals with early Alzheimer's Disease (AD) who are apolipoprotein E ε4 (ApoE ε4) non-carriers or heterozygotes" [The Journal of Prevention of Alzheimer's Disease (2026) 100507]Richard Perry, Christopher Kipps, Maria Eugenia Soto Martín, et al.
Human Molecular Genetics|March 26, 2002
Early phenotypes that presage late-onset neurodegenerative disease allow testing of modifiers in Hdh CAG knock-in miceVanessa C Wheeler, Claire-Anne Gutekunst, Vladimir Vrbanac, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 6, 2003
A cell-based assay for aggregation inhibitors as therapeutics of polyglutamine-repeat disease and validation in DrosophilaBarbara L Apostol, Alexsey Kazantsev, Simona Raffioni, et al.
Alzheimer'S Research & Therapy|May 10, 2024
Updated safety results from phase 3 lecanemab study in early Alzheimer's diseaseLawrence S Honig, Marwan N Sabbagh, Christopher H van Dyck, et al.
Alzheimer'S Research & Therapy|July 10, 2024
Correction: Updated safety results from phase 3 lecanemab study in early Alzheimer's diseaseLawrence S Honig, Marwan N Sabbagh, Christopher H van Dyck, et al.
Cell Reports|December 4, 2012
The sirtuin 2 inhibitor AK-7 is neuroprotective in Huntington's disease mouse modelsVanita Chopra, Luisa Quinti, Jinho Kim, et al.
Alzheimer'S Research & Therapy|April 23, 2026
Effects of the novel phosphodiesterase 9 inhibitor irsenontrine on CSF proteomics profile in Aβ<sup>+</sup> and Aβ<sup>-</sup> dementia with Lewy bodies patientsMarlies Oosthoek, Sjors G J G In 't Veld, Lisa Vermunt, et al.
Pageof 5

Showing results (31-40 of 47) with videos related to

Sort By:
Pageof 5
Neurobiology of Disease|July 12, 2014
Altered selenium status in Huntington's disease: neuroprotection by selenite in the N171-82Q mouse modelZhen Lu, Eileen Marks, Jianfang Chen, et al.
Plos Currents|September 30, 2010
Evaluation of histone deacetylases as drug targets in Huntington's disease models. Study of HDACs in brain tissues from R6/2 and CAG140 knock-in HD mouse models and human patients and in a neuronal HD cell modelLuisa Quinti, Vanita Chopra, Dante Rotili, et al.
The Journal of Prevention of Alzheimer'S Disease|February 14, 2026
Lecanemab for treatment of individuals with early Alzheimer's Disease (AD) who are apolipoprotein E ε4 (ApoE ε4) non-carriers or heterozygotesRichard Perry, Christopher Kipps, Maria Eugenia Soto Martín, et al.
The Journal of Prevention of Alzheimer'S Disease|March 14, 2026
Corrigendum to "Lecanemab for treatment of individuals with early Alzheimer's Disease (AD) who are apolipoprotein E ε4 (ApoE ε4) non-carriers or heterozygotes" [The Journal of Prevention of Alzheimer's Disease (2026) 100507]Richard Perry, Christopher Kipps, Maria Eugenia Soto Martín, et al.
Human Molecular Genetics|March 26, 2002
Early phenotypes that presage late-onset neurodegenerative disease allow testing of modifiers in Hdh CAG knock-in miceVanessa C Wheeler, Claire-Anne Gutekunst, Vladimir Vrbanac, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 6, 2003
A cell-based assay for aggregation inhibitors as therapeutics of polyglutamine-repeat disease and validation in DrosophilaBarbara L Apostol, Alexsey Kazantsev, Simona Raffioni, et al.
Alzheimer'S Research & Therapy|May 10, 2024
Updated safety results from phase 3 lecanemab study in early Alzheimer's diseaseLawrence S Honig, Marwan N Sabbagh, Christopher H van Dyck, et al.
Alzheimer'S Research & Therapy|July 10, 2024
Correction: Updated safety results from phase 3 lecanemab study in early Alzheimer's diseaseLawrence S Honig, Marwan N Sabbagh, Christopher H van Dyck, et al.
Cell Reports|December 4, 2012
The sirtuin 2 inhibitor AK-7 is neuroprotective in Huntington's disease mouse modelsVanita Chopra, Luisa Quinti, Jinho Kim, et al.
Alzheimer'S Research & Therapy|April 23, 2026
Effects of the novel phosphodiesterase 9 inhibitor irsenontrine on CSF proteomics profile in Aβ<sup>+</sup> and Aβ<sup>-</sup> dementia with Lewy bodies patientsMarlies Oosthoek, Sjors G J G In 't Veld, Lisa Vermunt, et al.
Pageof 5